Repurposing Terfenadine as a Novel Antigiardial Compound

<i>Giardia lamblia</i> is a highly infectious protozoan that causes giardiasis, a gastrointestinal disease with short-term and long-lasting symptoms. The currently available drugs for giardiasis treatment have limitations such as side effects and drug resistance, requiring the search for...

Full description

Bibliographic Details
Main Authors: Daniel Osmar Suárez-Rico, Francisco Javier Munguía-Huizar, Rafael Cortés-Zárate, José Manuel Hernández-Hernández, Sirenia González-Pozos, Armando Perez-Rangel, Araceli Castillo-Romero
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Pharmaceuticals
Subjects:
Online Access:https://www.mdpi.com/1424-8247/16/9/1332
Description
Summary:<i>Giardia lamblia</i> is a highly infectious protozoan that causes giardiasis, a gastrointestinal disease with short-term and long-lasting symptoms. The currently available drugs for giardiasis treatment have limitations such as side effects and drug resistance, requiring the search for new antigiardial compounds. Drug repurposing has emerged as a promising strategy to expedite the drug development process. In this study, we evaluated the cytotoxic effect of terfenadine on <i>Giardia lamblia</i> trophozoites. Our results showed that terfenadine inhibited the growth and cell viability of <i>Giardia</i> trophozoites in a time–dose-dependent manner. In addition, using scanning electron microscopy, we identified morphological damage; interestingly, an increased number of protrusions on membranes and tubulin dysregulation with concomitant dysregulation of <i>Giardia GiK</i> were observed. Importantly, terfenadine showed low toxicity for Caco-2 cells, a human intestinal cell line. These findings highlight the potential of terfenadine as a repurposed drug for the treatment of giardiasis and warrant further investigation to elucidate its precise mechanism of action and evaluate its efficacy in future research.
ISSN:1424-8247